Title : Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.

Pub. Date : 2014 May 12

PMID : 24819061






12 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. NAD lactate dehydrogenase A Homo sapiens
2 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
3 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
4 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
5 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
6 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
7 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
8 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
9 The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer"s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from reduced nicotinamide adenine dinucleotide (NADH) necessary to sustain glycolysis. NAD lactate dehydrogenase A Homo sapiens
10 Thus, LDH-A silencing by RNAi, or its inhibition using a small-molecule inhibitor, resulted in a p53-dependent increase in the cancer cell ratio of NADH:NAD(+). NAD lactate dehydrogenase A Homo sapiens
11 Thus, LDH-A silencing by RNAi, or its inhibition using a small-molecule inhibitor, resulted in a p53-dependent increase in the cancer cell ratio of NADH:NAD(+). NAD lactate dehydrogenase A Homo sapiens
12 To summarise, this work indicates two distinct mechanisms by which suppressing LDH-A could potentially be used to kill cancer cells selectively, (i) through induction of apoptosis, irrespective of cancer cell p53 status and (ii) as a part of a combinatorial approach with redox-sensitive anticancer drugs via a novel p53/NAD(H)-dependent mechanism. NAD lactate dehydrogenase A Homo sapiens